Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Pushes For Development Of Cancer Drugs (Japan)

This article was originally published in PharmAsia News

Executive Summary

Eisai Co. is accelerating its development of antibody drugs, hoping to leverage the technologies of U.S. subsidiary Morphotek Inc. to spur growth in the field of cancer treatment. Morphotek plans to begin by December phase II clinical testing of MORAb-009, an antibody that recognizes and binds to a cell-surface protein called mesothelin, which is strongly associated with the spread of cancer. The Eisai subsidiary is conducting safety and efficacy tests on MORAb-009 to treat pancreatic cancer, mesothelial cancer, small-cell lung cancer and ovarian cancer. The company will also start phase I clinical trials in fiscal 2008 for two other antibody drugs for cancer treatment: MORAb-028 to treat metastatic melanoma and MORAb-004 to prevent the formation of blood vessels that supply nutrients to tumors. (Click here for more - May Require Paid Subscription
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel